Sit Investment Associates’s Teva Pharmaceuticals TEVA Stock Holding History

Sit Investment Associates’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-392,500	Closed	-$18.1M	–	516
2016 Q3	$18.1M	Sell	392,500 -85,225	-18%	-$4.45M	0.48%	78
2016 Q2	$24M	Sell	477,725 -505,225	-51%	-$26.9M	0.64%	52
2016 Q1	$52.6M	Buy	982,950 +228,885	+30%	+$13.4M	0.96%	24
2015 Q4	$49.5M	Buy	754,065 +95,555	+15%	+$5.91M	0.93%	32
2015 Q3	$37.2M	Buy	658,510 +216,850	+49%	+$14.1M	0.69%	54
2015 Q2	$26.1M	Buy	+441,660	New	+$27.2M	0.48%	83

Other funds holding TEVA

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Barrow, Hanley, Mewhinney & Strauss Dallas, Texas $33B AUM 40.62% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

HCM

Highfields Capital Management Boston, Massachusetts $68.3M AUM 21.64% 1-Year Est. Return

Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Nordea Investment Management Stockholm, Sweden $123B AUM 38.85% 1-Year Est. Return

Sit Investment Associates's TEVA Position: Q4 2016 in Review

Sit Investment Associates sold out of Teva Pharmaceuticals (TEVA) in Q4 2016, closing a stake of 392,500 shares — an estimated $18.1M sold.

Sit Investment Associates first reported a position in TEVA in Q2 2015 and held it in 6 quarters. The position peaked at $52.6M in Q1 2016. 739 funds tracked by Wall St. Rank hold TEVA as of Q4 2016.

Sit Investment Associates reported no remaining Teva Pharmaceuticals position as of Q4 2016 after selling out during the quarter.
Sit Investment Associates sold 392,500 Teva Pharmaceuticals shares in Q4 2016, an estimated $18.1M.
Sit Investment Associates first reported a position in Teva Pharmaceuticals in Q2 2015 and held it in 6 quarters.
Sit Investment Associates's Teva Pharmaceuticals position peaked at $52.6M in Q1 2016.
739 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q4 2016.

Based on Sit Investment Associates's 13F filing for Q4 2016, filed 19 Jan 2017.